Abstract
Introduction The ineffective and unfortunate consequences of medication use, referred to as drug-related morbidity and mortality (DRM&M), are an insidious public health nemesis that has persisted for many years. It’s almost as if consumers perceive the unfortunate consequences of medication use as inevitable and a typical cost of doing business. The magnitude of this problem came to light with a study published in 1995 [1]. Additional research and analyses followed indicating that DRM&M is a nearly $(USD)300 billion annual burden in the United States [2-4]. In other words, we spend almost as much to fix the bad things that happen when patients take medications as we do to purchase pharmaceutical products.
Original language | English (US) |
---|---|
Title of host publication | Pharmaceutical Public Policy |
Publisher | Taylor and Francis |
Pages | 401-410 |
Number of pages | 10 |
ISBN (Electronic) | 9781498748513 |
ISBN (Print) | 9781498748506 |
DOIs | |
State | Published - Jan 1 2016 |